

Pawel Muranski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11458805/publications.pdf>

Version: 2024-02-01

56
papers

9,673
citations

126858

33
h-index

168321

53
g-index

56
all docs

56
docs citations

56
times ranked

13133
citing authors

#	ARTICLE	IF	CITATIONS
1	Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. <i>Nature Medicine</i> , 2009, 15, 808-813.	15.2	839
2	Tumor-specific Th17-polarized cells eradicate large established melanoma. <i>Blood</i> , 2008, 112, 362-373.	0.6	719
3	Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. <i>Journal of Clinical Investigation</i> , 2013, 123, 4479-4488.	3.9	719
4	Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. <i>Journal of Experimental Medicine</i> , 2010, 207, 637-650.	4.2	715
5	T Helper 17 Cells Promote Cytotoxic T Cell Activation in Tumor Immunity. <i>Immunity</i> , 2009, 31, 787-798.	6.6	679
6	Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. <i>Journal of Clinical Investigation</i> , 2007, 117, 2197-2204.	3.9	456
7	Th17 Cells Are Long Lived and Retain a Stem Cell-like Molecular Signature. <i>Immunity</i> , 2011, 35, 972-985.	6.6	392
8	Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma. <i>Journal of Experimental Medicine</i> , 2010, 207, 651-667.	4.2	389
9	Adoptively transferred effector cells derived from na ^{ve} rather than central memory CD8 ⁺ T cells mediate superior antitumor immunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 17469-17474.	3.3	348
10	Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go?. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 668-681.	4.3	318
11	Essentials of Th17 cell commitment and plasticity. <i>Blood</i> , 2013, 121, 2402-2414.	0.6	306
12	Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for Cellular Therapy. <i>Cell Metabolism</i> , 2016, 23, 63-76.	7.2	291
13	Akt Inhibition Enhances Expansion of Potent Tumor-Specific Lymphocytes with Memory Cell Characteristics. <i>Cancer Research</i> , 2015, 75, 296-305.	0.4	283
14	IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. <i>Journal of Clinical Investigation</i> , 2011, 121, 4746-4757.	3.9	283
15	Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. <i>Blood</i> , 2011, 117, 808-814.	0.6	272
16	Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy. <i>New England Journal of Medicine</i> , 2019, 380, 1597-1605.	13.9	260
17	Determinants of Successful CD8+ T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice. <i>Clinical Cancer Research</i> , 2011, 17, 5343-5352.	3.2	247
18	Increased Intensity Lymphodepletion Enhances Tumor Treatment Efficacy of Adoptively Transferred Tumor-specific T Cells. <i>Journal of Immunotherapy</i> , 2010, 33, 1-7.	1.2	236

#	ARTICLE	IF	CITATIONS
19	Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts. <i>Cancer Research</i> , 2010, 70, 6725-6734.	0.4	227
20	Adoptive immunotherapy of cancer using CD4+ T cells. <i>Current Opinion in Immunology</i> , 2009, 21, 200-208.	2.4	202
21	Type 17 CD8+ T cells display enhanced antitumor immunity. <i>Blood</i> , 2009, 114, 596-599.	0.6	196
22	Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy. <i>Journal of Clinical Investigation</i> , 2015, 126, 318-334.	3.9	193
23	Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the formation of memory CD8+ T cells. <i>Nature Immunology</i> , 2011, 12, 1230-1237.	7.0	165
24	Retinoic acid controls the homeostasis of pre-cDC-derived splenic and intestinal dendritic cells. <i>Journal of Experimental Medicine</i> , 2013, 210, 1961-1976.	4.2	120
25	Toll-like Receptors in Tumor Immunotherapy. <i>Clinical Cancer Research</i> , 2007, 13, 5280-5289.	3.2	114
26	Ultra-low Dose Interleukin-2 Promotes Immune-modulating Function of Regulatory T Cells and Natural Killer Cells in Healthy Volunteers. <i>Molecular Therapy</i> , 2014, 22, 1388-1395.	3.7	106
27	Genetic Engineering of Murine CD8+ and CD4+ T Cells for Preclinical Adoptive Immunotherapy Studies. <i>Journal of Immunotherapy</i> , 2011, 34, 343-352.	1.2	80
28	Memory Stem T Cells in Autoimmune Disease: High Frequency of Circulating CD8+ Memory Stem Cells in Acquired Aplastic Anemia. <i>Journal of Immunology</i> , 2016, 196, 1568-1578.	0.4	74
29	The clinical and financial burden of pre-emptive management of cytomegalovirus disease after allogeneic stem cell transplantation—implications for preventative treatment approaches. <i>Cytotherapy</i> , 2014, 16, 927-933.	0.3	56
30	Long term maintenance of myeloid leukemic stem cells cultured with unrelated human mesenchymal stromal cells. <i>Stem Cell Research</i> , 2015, 14, 95-104.	0.3	48
31	Mature CD4+ T Cells Perceive a Positively Selecting Class II MHC/Peptide Complex in the Periphery. <i>Journal of Immunology</i> , 2000, 164, 3087-3094.	0.4	42
32	Rapamycin is highly effective in murine models of immune-mediated bone marrow failure. <i>Haematologica</i> , 2017, 102, 1691-1703.	1.7	42
33	Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers. <i>Blood</i> , 2008, 112, 4746-4754.	0.6	39
34	A subset of virus-specific CD161+ T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AML. <i>Blood</i> , 2017, 129, 740-758.	0.6	35
35	Identification of novel microRNA signatures linked to acquired aplastic anemia. <i>Haematologica</i> , 2015, 100, 1534-1545.	1.7	29
36	Does IL-17 promote tumor growth?. <i>Blood</i> , 2009, 114, 231-232.	0.6	26

#	ARTICLE	IF	CITATIONS
37	Activation of Th1 Immunity within the Tumor Microenvironment Is Associated with Clinical Response to Lenalidomide in Chronic Lymphocytic Leukemia. <i>Journal of Immunology</i> , 2018, 201, 1967-1974.	0.4	22
38	PPAR α antagonist attenuates mouse immune-mediated bone marrow failure by inhibition of T cell function. <i>Haematologica</i> , 2016, 101, 57-67.	1.7	20
39	T cell therapies for human polyomavirus diseases. <i>Cytotherapy</i> , 2017, 19, 1302-1316.	0.3	17
40	Timing and intensity of exposure to interferon γ critically determines the function of monocyte-derived dendritic cells. <i>Immunology</i> , 2014, 143, 96-108.	2.0	13
41	Over-expression of PD-1 Does Not Predict Leukemic Relapse after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 216-222.	2.0	11
42	Adenosine Selectively Depletes Alloreactive T Cells to Prevent GVHD While Conserving Immunity to Viruses and Leukemia. <i>Molecular Therapy</i> , 2016, 24, 1655-1664.	3.7	8
43	Clinical and biological predictors of outcome following relapse of CML post-allo-SCT. <i>Bone Marrow Transplantation</i> , 2015, 50, 189-196.	1.3	7
44	Ex vivo T-cell-depleted allogeneic stem cell transplantation for hematologic malignancies: The search for an optimum transplant T-cell dose and T-cell add-back strategy. <i>Cytotherapy</i> , 2017, 19, 735-743.	0.3	5
45	Cellular immune profiling after sequential clofarabine and lenalidomide for high risk myelodysplastic syndromes and acute myeloid leukemia. <i>Leukemia Research Reports</i> , 2017, 7, 40-44.	0.2	5
46	Myeloid Leukemias Directly Suppress T Cell Proliferation Through STAT3 and Arginase Pathways. <i>Blood</i> , 2013, 122, 3885-3885.	0.6	5
47	Genetically engineered fixed K562 cells: potent off-the-shelf antigen-presenting cells for generating virus-specific T cells. <i>Cytotherapy</i> , 2014, 16, 135-146.	0.3	4
48	Distinct Biomarker Profiles in Ex Vivo T Cell Depletion Graft Manipulation Strategies: CD34+ Selection versus CD3+/19+ Depletion in Matched Sibling Allogeneic Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 460-466.	2.0	3
49	Ultra-Low Dose IL-2 Safely Expands Regulatory T Cells and CD56bright NK Cells in Healthy Volunteers: Towards Safer Stem Cell Donors?. <i>Blood</i> , 2012, 120, 3283-3283.	0.6	2
50	Selective Depletion of Alloreactive Donor T Cells with Adenosine: An Efficient, Scaleable, GMP-Compliant, Low-Cost Method to Prevent Gvhd While Preserving Antiviral and Antileukemic Activity in Haploidentical Stem Cell Transplant. <i>Blood</i> , 2015, 126, 380-380.	0.6	2
51	Alemtuzumab Achieved Durable Hematologic Response In Heavily Treated T-Large Granular Lymphocytosis Irrespective To STAT3 Mutation Or V-Beta Clone Size. <i>Blood</i> , 2013, 122, 3705-3705.	0.6	1
52	Ex Vivo Generation Of CD4+ T Cells To Prevent and Treat Infection From Antibiotic-Resistant Klebsiella Pneumoniae In Immunocompromised Patients. <i>Blood</i> , 2013, 122, 2022-2022.	0.6	1
53	Ex Vivo Generation of CD4+ Th17 Cells to Prevent and Treat Infection from Antibiotic-Resistant Klebsiella Pneumoniae in Immunocompromised Patients. <i>Blood</i> , 2014, 124, 2445-2445.	0.6	1
54	An easy way to make a good anti-tumor chimeric antigen receptor T cell?. <i>Cytotherapy</i> , 2014, 16, 577-578.	0.3	0

#	ARTICLE	IF	CITATIONS
55	High Frequency of Circulating CD8+ Memory Stem T Cells in Acquired Aplastic Anemia. Blood, 2015, 126, 3613-3613.	0.6	0
56	Safety and Feasibility of Ultra-Low Dose IL-2 As Graft Versus Host Disease Prophylaxis in Haplo-Identical Stem Cell Transplantation- a Proof of Concept Pilot Study. Blood, 2016, 128, 386-386.	0.6	0